SpringWorks Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing and commercializing medicines for serious rare diseases and cancer. The company is developing an oral small molecule gamma secretase inhibitor as a monotherapy for the treatment of soft tissue desmoid tumors, and an oral small molecule MEK inhibitor for the treatment of neurofibromatosis type 1. The company is based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 227 |
Founded | 2017 |
Financials | |
|---|---|
Market Capitalization | 3.07B |
Revenue | 26.45M |
Operating Income | -359.25M |
Operating Margin | -1358.05% |
Net Income | -339.07M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 5226 / 5373 |
Sector : Healthcare | 1095 / 1144 |
Industry : Biotechnology | 614 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 1605 / 5565 |
Sector : Healthcare | 182 / 1182 |
Industry : Biotechnology | 53 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 5232 / 5436 |
Sector : Healthcare | 1113 / 1164 |
Industry : Biotechnology | 631 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 3487 / 5330 |
Sector : Healthcare | 440 / 1174 |
Industry : Biotechnology | 128 / 667 |